ArticleBMC pharmacology & toxicology2017

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.

Chih-Jen Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.